Insmed Signals Paradigm Shift with Landmark European Bronchiectasis Study

HANNOVER, Germany – June 25, 2026 – In a move that signals a significant escalation in the fight against chronic lung disease, Insmed Incorporated and the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) today announced their intention to launch a landmark study. The collaboration, unveiled at the World Bronchiectasis Conference, will evaluate whether Insmed's recently approved drug, brensocatib, can do more than just manage symptoms—it will investigate if the therapy can fundamentally modify the course of bronchiectasis.

The planned three-year, open-label study is ambitious in its scale, aiming to enroll up to 3,000 patients across six European nations. For Insmed, this represents a powerful growth signal: a strategic, multi-million-dollar investment to move beyond its recent regulatory victories and solidify its drug as a transformative force in respiratory medicine.

A New Horizon for a Neglected Disease

For decades, bronchiectasis has been a historically overlooked condition, leaving its sufferers in a debilitating cycle of chronic inflammation and infection. The disease, which affects approximately 600,000 people in Europe and millions globally, is characterized by the permanent widening of airways, leading to a "vicious vortex" of impaired mucus clearance, recurrent bacterial infections, and progressive lung damage. Patients endure a daily burden of coughing, excessive sputum, and shortness of breath, punctuated by severe flare-ups, or exacerbations, that accelerate lung function decline and increase mortality risk.

Until last year, no targeted therapies were approved for the condition. The standard of care was limited to managing the consequences—airway clearance techniques, long-term antibiotic regimens, and pulmonary rehabilitation. This therapeutic void changed dramatically in 2025 when Insmed secured landmark FDA and European Commission approvals for brensocatib, making it the first-ever approved treatment specifically for non-cystic fibrosis bronchiectasis.

From Symptom Control to Disease Modification

Brensocatib's initial success was built on the robust results of the pivotal Phase 3 ASPEN trial, the largest ever conducted in the disease. The data, published in The New England Journal of Medicine, showed that brensocatib, a first-in-class oral inhibitor of the enzyme DPP-1, significantly reduced the frequency of exacerbations. By blocking DPP-1, the drug prevents the activation of destructive neutrophil enzymes that drive inflammation, a novel mechanism of action. Even more critically, the 25 mg dose demonstrated an ability to slow the rate of lung function decline—the first clear signal that it could be more than just a symptomatic treatment.

This new study with EMBARC aims to answer the next logical, and far more profound, question. It's a direct challenge to the historical definition of bronchiectasis as an incurable, progressively worsening condition.

"Building on ASPEN trial data... this study through the EMBARC network will allow us to ask an even more ambitious question: whether intervening earlier in the disease course can do more than slow progression, but fundamentally alter its trajectory,” said lead study investigator James Chalmers, MBChB, Ph.D., of the University of Oxford. “Over a three-year horizon, we have a real opportunity to understand whether earlier use of brensocatib can... change the natural course of the disease. That is the question at the heart of this study, and the answer could help shape how we treat bronchiectasis in the future."

The Power of Collaborative Scale

The study's design—a large-scale, long-term, open-label trial—is tailored to this ambitious goal. While not the randomized, placebo-controlled format required for initial approval, this design is ideal for gathering the real-world evidence needed to understand long-term safety, effectiveness, and the potential for disease modification across a broad patient population.

The partnership with EMBARC is a critical component of this strategy. As Europe’s preeminent bronchiectasis research network, EMBARC provides the infrastructure, clinical expertise, and patient access across the United Kingdom, Spain, Germany, Belgium, France, and Italy necessary to execute a study of this magnitude. This is not merely a corporate trial; it is a strategic alliance between industry and academia, lending significant scientific credibility to the endeavor.

"EMBARC is one of the world's leading bronchiectasis research networks, and this collaboration reflects our commitment to understanding how brensocatib can make the greatest possible difference in patients' lives,” said Martina Flammer, M.D., MBA, Chief Medical Officer at Insmed. "Together with the scientific and patient community, we are uniquely positioned to help shape clinical advancement."

Decoding the Growth Signal

For executives and investors, this announcement is a clear signal of Insmed's long-term strategy. The company is not content to simply monetize its first-in-class approvals. Instead, it is aggressively investing to build a durable competitive moat around brensocatib, aiming to establish it as the undisputed standard of care for decades to come.

The strategic drivers are clear. First, proving disease modification would elevate brensocatib from a breakthrough therapy to a truly foundational one, securing its place in treatment guidelines. Second, the wealth of real-world data generated will be invaluable for negotiating with national health authorities on reimbursement and access, a crucial step in unlocking the drug's full commercial potential in Europe. With a U.S. list price of approximately $88,000 per year, demonstrating profound long-term value is paramount.

Finally, by exploring earlier use and employing novel composite endpoints, Insmed is signaling its intent to not only lead the market but also advance the underlying science of the disease itself. This positions the company as a thought leader and a committed partner to the patient community. For a company on the move, this collaboration shows Insmed is looking far beyond the next quarter's earnings, focusing instead on a transformational clinical outcome that could secure its growth trajectory for the next decade.